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Abstract
Marijuana is the most widely used illicit substance in those diagnosed with bipolar I disorder.
However, there is conflicting evidence as to whether marijuana may alleviate or exacerbate
mood symptomatology. As bipolar disorder and marijuana use are individually associated
with cognitive impairment, it also remains unclear whether there is an additive effect on cog-
nition when bipolar patients use marijuana. The current study aimed to determine the impact
of marijuana on mood in bipolar patients and to examine whether marijuana confers an
additional negative impact on cognitive function. Twelve patients with bipolar disorder who
smoke marijuana (MJBP), 18 bipolar patients who do not smoke (BP), 23 marijuana smok-
ers without other Axis 1 pathology (MJ), and 21 healthy controls (HC) completed a neuro-
psychological battery. Further, using ecological momentary assessment, participants rated
their mood three times daily as well as after each instance of marijuana use over a four-
week period. Results revealed that although the MJ, BP, and MJBP groups each exhibited
some degree of cognitive impairment relative to HCs, no significant differences between the
BP and MJBP groups were apparent, providing no evidence of an additive negative impact
of BPD and MJ use on cognition. Additionally, ecological momentary assessment analyses
indicated alleviation of mood symptoms in the MJBP group after marijuana use; MJBP par-
ticipants experienced a substantial decrease in a composite measure of mood symptoms.
Findings suggest that for some bipolar patients, marijuana may result in partial alleviation of
clinical symptoms. Moreover, this improvement is not at the expense of additional cognitive
impairment.
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Introduction
Bipolar disorder (BPD), considered one of the most debilitating mood disorders, is the sixth
leading cause of disability in the world according the World Health Organization. In those
affected, BPD is often a significant source of distress and burden on relatives and caregivers
[1]. Further, among Axis I pathologies, BPD carries the highest risk of substance use comorbid-
ity, which can complicate the course of illness and impact treatment outcomes. In fact, patients
with co-occurring BPD and substance use often experience poor treatment response, relapse of
mood symptoms, psychosocial difficulties, and reduced treatment compliance [2–4]. Despite
evidence that suggests substance use is linked to poorer outcomes, some studies have also
shown that BPD patients engage in substance use to improve clinical symptoms. Bolton and
colleagues [5] found that almost a quarter of those with mood disorders used alcohol or drugs
to relieve symptoms, with the highest rates of self-medication seen in bipolar I disorder. In
another study, the authors found that specifically amongst BPD patients who use substances,
79% engaged in drug use specifically to improve mood symptoms [6].
Marijuana (MJ) is the most commonly used illicit substance in the US; this statistic also
holds true among those diagnosed with BPD [7]. Moreover, rates of MJ use disorders in BPD
patients have been found to equal or exceed those of alcohol abuse or dependence, particularly
in younger patients [8]. Research has also shown that 20–50% of patients report some form of
MJ-related problems [9]. In those who endorse MJ-related problems, 63.7% reported disability,
as compared to only 44.5% of those not meeting criteria for MJ use disorders, supporting previ-
ous findings that patients with BPD who engage in MJ use exhibit reduced compliance, higher
levels of illness severity, and increased likelihood to attempt suicide [4, 7–8, 10–12].
While these studies appear to suggest that MJ use results in negative outcomes, a specific
cause-and-effect relationship has yet to be determined. Although many studies have reported
that MJ use precedes the onset of BPD [13–16], it remains unclear whether MJ use contributes
to the pathogenesis of the disorder, or if it is used to address symptomatology, perhaps as a
form of premorbid self-medication [17–19], especially if traditional pharmacotherapeutic regi-
mens are ineffective at symptom alleviation. Others have also reported that individuals with
higher levels of illness severity may be at risk for MJ use after the onset of the disorder [20].
Further research is needed to clarify the relationship between MJ use and the manifestation of
BPD symptoms. Despite claims of negative outcomes associated with MJ use, whether patients’
view MJ use as successful in symptom improvement is rarely assessed. In a single study of BPD
patients, Weiss et al. [21] reported that nearly all patients initiated substance use as the result of
one bipolar symptom, and the majority of patients reported improvement that was attributable
to substance use for at least one symptom. Further, in a review of anecdotal reports of MJ use
among BPD patients, the authors concluded that MJ was not utilized for the “high” sought out
by recreational users, which may suggest that the effects of MJ are unique in sub-euphoric
doses [22]. Regardless of the motive for use, the fact remains that MJ use is common in patients
with BPD. As noted above, patients with BPD who use MJ have been shown to have higher ill-
ness severity and poorer outcome, yet report subjective improvement in symptoms after using
MJ, suggestive of a complex relationship between MJ and mood [23]. Taken together, these
data provide evidence that some patients with BPD may derive a clinical benefit from using MJ
and highlight the importance of understanding the effects of MJ on mood symptomatology in
those diagnosed with affective disorders.
Ecological Momentary Assessment (EMA), utilized in the current study, allows for the
investigation of real-time assessment of mood and related symptoms as well as repeated collec-
tion of real-time data in participants' natural environment [24–25]. While most symptom
assessments and diagnostic tools in both research and clinical settings rely on retrospective
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recall of emotions and symptomatology using interviews and self-report questionnaires, EMA
data is collected in naturalistic, real-world contexts and therefore offers improved ecological
validity over traditional, retrospective methods. In fact, retrospective reports of mood have
been shown to have a bias towards negative mood states such as anxiety, depression, and help-
lessness [26]. Collecting data in real-time with EMA reduces error bias from retrospective
assessment and limits the effects of recall bias and generalization of symptoms over a period of
time (Shiffman et al., 2008). Additionally, in a review article assessing the contribution of EMA
on psychopathology research, Myin-Germeys and colleagues [27] suggest that symptoms in
psychiatric disorders are dynamic and can meaningfully fluctuate through the course of the
day. Thus, the increased ecological validity of EMA tools can provide better insight into the
phenomenology and etiology of psychopathology than retrospective techniques. Better under-
standing of the development, maintenance, and progression of symptoms may lead to
improved models of these disorders and help inform future treatment strategies [27].
Given a growing body of research indicating cognitive deficits associated with MJ use, it is
also important to explore the impact of MJ across various cognitive domains. Interestingly, MJ
users (without Axis I pathology) and BPD patients (who do not necessarily smoke MJ) have
been shown to exhibit similar cognitive deficits. MJ use has been linked to impairments across
a wide range of areas, including attention [28], memory [29–31], IQ [32–34], and executive
function [35–37]. Similarly, BPD patients often evidence cognitive deficits across multiple
overlapping domains; in two meta-analyses of euthymic BPD patients [38–39], the authors
note marked impairment relative to healthy controls on measures of executive function, verbal
memory, and attention. Despite the fact that MJ use and a diagnosis of BPD are both individu-
ally related to cognitive deficits, two studies examining neurocognitive function in MJ-smoking
patients with BPD report surprising outcomes. Both Ringen et al. [40] and Braga, Burdick,
DeRosse, and Malhotra [41] reported a positive association between neuropsychological func-
tioning and MJ use in BPD patients, perhaps suggestive of a unique relationship between BPD
and MJ use. Specifically, Ringen and colleagues [40] examined a variety of cognitive domains,
including psychomotor speed, attention, working memory, executive functioning, and verbal
learning. Overall, BPD patients who used MJ demonstrated better performance than patients
who did not use MJ, although statistically significant results were only observed on tests of
executive function. Similarly, Braga et al. [41] reported neurocognitive advantages in MJ-smok-
ing BPD patients, relative to a non-smoking BPD group, spanning several domains, including
executive function (Trails B) as well as attention and working memory. These results suggest
that despite a more severe clinical course, BPD patients who use MJ may demonstrate a cogni-
tive advantage relative to patients without a history of MJ use, underscoring the need for addi-
tional investigation.
Through EMA and a comprehensive neuropsychological battery, the current study aimed to
clarify the relationship between acute MJ use and mood symptoms as well as cognitive function
in patients with BPD. In order to accurately assess the impact of MJ use, BPD diagnosis, and
the additive effects of both MJ use and BPD, we utilized a four-group study design enrolling
healthy control subjects without MJ use or Axis I disorders (HC), MJ smokers without other
Axis I disorders (MJ), individuals diagnosed with BPD without a history of MJ use (BP), and
those diagnosed with BPD who currently used MJ (MJBP). We expected, in line with previous
research, that the BP and MJBP groups would have more severely affected mood overall rela-
tive to the HC group. However, we further hypothesized that the MJBP group would experi-
ence significant mood improvement secondary to MJ use. In addition, although previous
studies have shown that MJ use is related to cognitive deficits, there is a relative paucity of liter-
ature focused on the association between MJ use and cognitive function in patients with BPD.
Therefore, the current study also aimed to determine whether MJ use has a differential effect
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on cognitive performance in pure MJ smokers, BPD patients who smoke MJ (MJBP), and BPD
patients who do not use MJ (BP).
Materials and Methods
Prior to participation, study procedures were thoroughly explained. All participants were also
required to read and sign an informed consent form, a document that describes the procedures,
risks, benefits, and voluntary nature of the study. This study and all study procedures were
approved by the McLean Hospital Institutional Review Board.
Participants
As part of a larger study conducted between 2008 and 2014, 21 healthy control subjects (HC),
23 MJ smokers without other Axis 1 pathology (MJ), 18 individuals with bipolar I disorder
who do not smoke MJ (BP), and 12 individuals diagnosed with bipolar I disorder who smoke
MJ (MJBP), were enrolled and completed neuropsychological assessments. A subset of these
participants also completed daily EMA assessments over the course of four weeks to assess
mood.
Participants were not enrolled in the current study if they met criteria for any Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV-TR) Axis I pathology (with the exception
of bipolar I disorder in the BPD groups, and MJ abuse/dependence in the MJ-smoking groups),
as assessed by the Structured Clinical Interview for DSM-IV, Patient Edition (SCID-P) [42].
Individuals were also excluded if they reported a neurological disorder or significant medical
problems, significant head injury with loss of consciousness, or were non-native English speak-
ers (as necessitated by the cognitive assessment battery). Further, no participant was enrolled if
they reported more than 15 lifetime uses of any illicit drugs (except MJ for the smoking groups)
or recreational use of prescription or over-the-counter (OTC) medications, or had received
electroconvulsive therapy.
Subjects enrolled in the MJ and MJBP groups were all well-characterized as chronic MJ
smokers who reported smoking a minimum of 2,500 times in their lives, used MJ at least four
out of the last seven days and tested positive for urinary cannabinoids. In order to ensure that
cognitive test results were not affected by acute intoxication, all participants were also required
to abstain fromMJ use for at least twelve hours prior to study visits. Upon arrival, all individu-
als were required to provide a urine sample and, to ensure adherence to the twelve-hour absti-
nence requirement, were led to believe that this sample could be used to detect use within this
time frame. This method has previously been used by our laboratory with success [36, 43–44].
Subjects were assessed for most recent use and any who violated the abstinence schedule or
who appeared even vaguely intoxicated were rescheduled for a later date. An aliquot of the
urine sample was sent to an outside laboratory for quantification of urinary cannabinoid con-
centration via gas chromatography–mass spectrometry during the initial and final study visit.
Urinary THC levels were averaged across the two study visits.
Study Design and Measures
After completing diagnostic assessments, subjects who met inclusion criteria were enrolled in
the four-week study, which contained a baseline visit and four weekly check-in visits. This
study employed a combination Time-Based EMA design and Event-Based Monitoring [24–
25]. The Time-Based EMA employed an alarm schedule, which alerted participants to com-
plete three rating sessions per day. Each subject pre-selected three times throughout the day (at
least five hours apart), which were tailored to his/her typical daily schedules, to rate their
mood. In Event-Based Monitoring, EMA measures are triggered by the occurrence of a specific
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event. For this study, participants were instructed to complete rating scales as soon as possible
after MJ use in order to assess the acute impact of MJ on mood.
At the end of their initial screening study visit, all enrolled participants were issued a Palm
Pilot (Palm Tungsten T5 PalmOne PDA) and instructed to use the device to rate their mood
three times daily over the course of the four-week study. All individuals rated their mood using
a custom-designed application, which contained electronic versions of several clinical rating
scales: the Profile of Mood States (POMS) [45], which yields subscores for vigor, anger, confu-
sion, tension, fatigue, depression, and a composite score for total mood disturbance (TMD);
the Hamilton Anxiety Rating Scale (HAM-A) [46]; Montgomery-Asberg Depression Rating
Scale (MADRS) [47]; and the Young Mania Rating Scale (YMRS) [48]. Participants who
smoked MJ were also asked to use the device to record episodes of MJ use to allow for the cal-
culation of pre- and post-MJ use mood changes. More specifically, for each episode of MJ use,
participants recorded the amount (in grams), frequency, and mode of MJ use (bong, bowl,
joint, etc.). Date and time were automatically recorded at the completion of each scale in order
to assist with accurate pre- and post-smoking determinations. However, participants were also
given the option to adjust the time of last MJ use when completing post-use ratings. Only rat-
ings identified as being completed within four hours of MJ use were categorized as post-MJ use
and used for analysis. To ensure that participants were not arbitrarily answering clinical rating
questions, “quality control” questions were interspersed throughout the scales, with such ques-
tions such as “who is the current US president?” and “how thoughtfully are you answering
these questions?”
In order to establish an estimate of overall intellectual functioning, participants completed
the Wechsler Abbreviated Scale of Intelligence (WASI) [49]. In addition, all individuals
enrolled also completed a neuropsychological battery designed to assay a variety of cognitive
domains. Neuropsychological assessments were typically completed by the end of the first
check-in visit, and consisted of a number of measures including the Wisconsin Card Sorting
Test (WCST), Trail Making Test, Stroop Color Word Test, the Controlled Oral Word Associa-
tion Test (COWAT), and Digit Span, which served as direct measures of executive function.
The WCST assesses the ability to form abstract concepts, shift and maintain set, and utilize
feedback, and is considered a gold-standard measure of executive function [50–51]. The Trail
Making Test is comprised of two parts; while Trails A measures visual scanning and psycho-
motor speed, Trails B serves as a measure of cognitive set-shifting and attention [51]. The
Stroop measures the ability to establish competing response tendencies, inhibit inappropriate
responses, and resist interference [52]. The COWAT consists of two parts and serves as a mea-
sure of phonemic verbal fluency and executive function (participants must generate words
starting with the specific letters F, A, and S) as well as verbal memory function (participants are
required to generate words from a specific semantic category, in this case “Animals”) [53–54].
The Digit Span subtest from the Wechsler Adult Intelligence Scale—Revised (WAIS-R),
requires subjects to recall increasingly longer strings of numbers in forward and then backward
order, and reflects attention, working memory and executive functioning [55–56].
Study participants also completed additional cognitive measures, including the California
Verbal Learning Test (CVLT), Rey-Osterrieth Complex Figure Test (ROCF), and Hooper
Visual Organization Test (HVOT). The CVLT-II requires subjects to learn an orally presented
list of words across five trials to assess verbal learning [57]. Errors and clustering strategies (i.e.,
grouping list items by category) are also documented to assess efficiency of learning. Further,
the CVLT incorporates a delay trial, in which individuals are required to remember the list of
words after a 20-minute delay in order to assess verbal memory. The ROCF assesses visual-spa-
tial organization as well as visual memory and requires individuals to copy a complex figure
and then draw it from memory both immediately and after a twenty-minute delay [51]. Finally,
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the HVOT, a measure of visuoperception, requires participants to name objects in drawings
that have been “cut” into pieces [58].
In addition, study participants completed the Fagerström Test for Nicotine Dependence
(FTND) [59] in order to assess current level of nicotine use and level of dependence. The
Addiction Severity Index (ASI) [60] was administered to calculate days of alcohol use within
the past month. In order to assess average frequency and magnitude of MJ use, a modified
timeline follow-back procedure [61] was utilized at weekly study visits, with a specific focus on
the past week of use. Participants were asked to report the number of times they smoked MJ,
the amount of MJ used (in grams) and the mode of use each time (i.e., joint, blunt, bong, etc.).
Lifetime use was also assessed using the SCID-P and guided substance use interviews.
Statistical Analyses
In order to ensure that groups were well-matched, one-way analyses of variance (ANOVAs)
with Scheffé all pairwise post hoc comparisons (two-tailed) were used to compare the four
groups on all continuous demographic variables: age, IQ, ASI alcohol use (days/month), and
FTND. As analyses identified age as a potential confounding variable, analyses of covariance
(ANCOVAs) controlling for age were performed for all comparisons in which age was signifi-
cantly different between the groups. In addition, chi-squared analyses were used to compare
the sex frequencies between the four groups and to compare medication in the BP and MJBP
groups. One-way ANOVAs (two-tailed) were conducted to compare age of BP onset in the BP
and MJ BP groups, as well as MJ use variables in the MJ and MJBP groups, including age of MJ
onset (defined as first regular use: a measurable, consistent pattern of use that occurred at least
monthly); frequency of MJ use (average number of smoking episodes per week); magnitude of
MJ use (average amount, in grams, used each week); duration of use (number of years since
onset of regular MJ use); and urinary THC concentration (ng/mL).
EMA analyses
Average mood scores over the entire four-week EMA data collection period were calculated for
all clinical rating scales for each individual. Additionally, for MJ-smoking participants (MJ &
MJBP groups), clinical rating scales were coded to indicate whether each rating was collected
before (pre) or after (post) MJ use and, with this information, “average pre-MJ use” and “aver-
age post-MJ use” ratings scales were calculated for each individual. As previously mentioned, a
four-hour threshold was utilized, such that all scales completed within four hours of MJ use
were coded as post-MJ use ratings. Ratings completed before MJ use each day, as well as those
completed in excess of four hours after MJ use were labeled as pre-MJ use ratings. In an effort
to obtain at least one daily baseline rating per day, participants were asked to complete their
first set of clinical rating scales prior to smoking MJ. Obtaining overall mood rating averages
for each individual, as well as pre- and post-MJ use ratings in the MJ and MJBP participants,
provided the opportunity to conduct several levels of analyses in order to assess the unique
effects of MJ and BPD on mood, as described below.
One-way ANCOVAs controlling for age were used to analyze differences between the four
groups. In order to reduce the number of unnecessary pairwise comparisons, one-tailed Dun-
nett t post hoc comparisons were employed to compare each group to the HC control group.
More specifically, to assess the effects of MJ use on both mood and cognition, the HC and MJ
groups were directly compared. Similarly, the effect of BPD was examined by comparing the
HC group to the “pure” BP group. The additive effect of MJ use and BPD was assessed by com-
paring the HC group to the MJBP group, and additional one-way ANCOVAs (one-tailed) were
also conducted in order to compare the BP group to the MJBP group. These analyses were
Marijuana, Bipolar Disorder, Mood, and Cognition
PLOS ONE | DOI:10.1371/journal.pone.0157060 June 8, 2016 6 / 23
performed on the overall average mood ratings from the EMA data and, to determine whether
significant between-groups differences in overall mood were affected by MJ use, ANCOVAs
were repeated using the pre-MJ use average mood ratings, and again using the post-MJ use
average mood ratings from the MJ-using groups (MJ and MJBP). In addition, in order to inves-
tigate the acute effects of MJ on mood within both the MJ and MJBP groups, pre-MJ use aver-
age mood scores were compared to post-MJ use average mood scores using paired t tests (one-
tailed) in each of these two groups separately.
EMA compliance analyses and controlling for missing data. Compliance checks were
completed during weekly visits and involved saving the EMA data from the PDA to ensure that
subjects were completing the majority of their scales. Subjects were informed of their level of
compliance at each check-in visit and were encouraged to complete as many scales as possible
during the following week. Overall compliance percentages were calculated for each subject.
One-way ANOVAs with two-tailed Scheffé all pairwise post hoc comparisons were used to
assess compliance percentage differences between the four groups. Additionally, two-tailed
Pearson correlations between compliance percentage and EMA average rating scales were used
to ensure that missing data did not significantly impact or skew the study findings.
Neuropsychological assessment statistical analyses. To examine the effect of BPD on
cognition, regardless of MJ use status, one-way two-group ANCOVAs (2-tailed) controlling
for age were performed to compare HC participants to participants with BPD (BP and MJBP
groups combined). One-way, three-group ANCOVAs with Scheffé all-pairwise post hoc com-
parisons (2-tailed) were also conducted to compare the HC, BP, and MJBP participants. These
three-group analyses assessed the impact of BPD on cognition exclusive of MJ use (HC vs BP),
and addressed any potential additive effects of MJ use in BP patients (HC vs MJBP and BP vs
MJBP).
Results
Demographics
Demographics are reported in Table 1. ANOVAs of demographic variables between the four
groups revealed that the groups were well matched for IQ and alcohol use (days/month).
Between-group differences were noted for age (F(3,70) = 5.819, p = .001); Scheffé post hoc
comparisons indicated that the BP subjects were significantly older than both HC (p = .029),
and MJ (p = .002) participants. Accordingly, age differences were controlled for by utilizing
ANCOVAs in all analyses of mood and cognitive performance. Chi-squared analyses indicated
that the groups were not well matched for sex (X2(3, N = 74) = 11.628, p = .009) with the MJBP
group having a significantly lower percentage of females than the HC (X2(1, N = 33) = 8.972, p
= .003) and BP groups (X2(1, N = 30) = 6.914, p = .009). Average scores on the FTND reflected
very low nicotine use across the groups. However, between-group differences were noted (F
(3,70) = 6.335, p = .001); the MJBP group reported significantly more nicotine use relative to
the HC (p = .002), MJ (p = .019) and BP (p = .004) groups. All of the other groups reported sim-
ilar FTND scores to one another, and given such low use indicated by the total scores, even for
the MJBP group (M = 1.92, SD = 3.00), it is unlikely that nicotine use was a confound for subse-
quent analyses.
Analyses of medication use revealed that the BP and MJBP groups reported similar medica-
tion regimens (Table 2). No significant differences were noted for the frequency of use of
different classes of medications: mood stabilizers, antidepressants, antipsychotics, and benzodi-
azepines. There were also no significant differences between the BP and MJBP groups for the
number of medicated vs unmedicated patients within each group. In addition, the BP and
MJBP groups were well-matched for age of BPD onset. With regard to MJ use characteristics,
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the MJ and MJBP groups were also well-matched for age of MJ onset (Table 1), as well as cur-
rent levels of MJ use. In fact, no significant differences emerged between groups for frequency
(smokes/week) and magnitude of MJ use (grams/week), duration of MJ use (years since onset
of regular use), or urinary THC levels (ng/mL).
EMA Results
EMA compliance results and controlling for missing data. Across all groups, high levels
of compliance were noted for rating scale completion, with the average overall number of com-
pleted rating scales at 88% of all possible rating opportunities. Within the HC group, EMA rat-
ing compliance indicated that they completed 94% of scales, while the BP completed 90%, and
the MJ and MJBP groups each completed 84% of scales. Notably, the MJ and MJBP groups
both were required to complete more rating scales than the non-smoking groups, as they rated
their mood three times daily in addition to completing ratings after MJ use. Therefore, it is not
Table 1. ANOVAs for 4-group comparison of demographic data (2-tailed).
Variable HC MJ BP MJBP ANOVA Scheffé All Pairwise Post Hoc Comparisons
F p (η2) HC v
MJ
HC v
BP
HC v
MJBP
MJ v
BP
MJ v
MJBP
BP v
MJBP
n Sex 21 (8M,
13F)
23 (16M,
7F)
18
(8M,10F)
12
(11M,1F)
- - - - - - - -
Age 23.38
(4.20)
21.96
(5.07)
28.56
(6.70)
23.75 (4.45) 5.819 .001
(.200)
NS .029 NS .002 NS NS
IQ 124.65
(8.15)
119.61
(14.35)
119.17
(9.92)
115.00
(9.62)
1.948 .130
(.079)
NS NS NS NS NS NS
Alcohol Use
(days/month)
5.24
(5.44)
7.18 (6.05) 3.94 (5.71) 5.17 (4.71) 1.133 .342
(.048)
NS NS NS NS NS NS
BPD Age of
Onset
- - 18.06
(4.53)
15.21 (3.17) 3.556 .070
(.113)
- - - - - -
MJ Age of Onset - 16.35
(2.31)
- 16.92 (2.61) 0.438 .513
(.013)
- - - - - -
MJ Smokes/
Week
- 15.99
(7.39)
- 15.55
(13.63)
0.015 .903
(<.001)
- - - - - -
MJ Grams/Week - 7.21 (5.55) - 5.19 (2.76) 1.289 .265
(.039)
- - - - - -
MJ Duration of
Use (yrs)
- 5.61 (3.99) - 6.83 (2.76) 0.901 .349
(.027)
- - - - - -
Urinary THC
(ng/mL)
- 617.53
(873.71)
- 443.13
(528.43)
0.370 .547
(.011)
- - - - - -
doi:10.1371/journal.pone.0157060.t001
Table 2. Chi Squared Analyses of Medication Use in the BP andMJBP Groups.
Variable BP MJBP Chi Squared
X2 p
Mood Stabilizers 72.22% 75.00% 0.028 NS
Antidepressants 27.78% 16.67% 0.497 NS
Antipsychotics 55.56% 58.33% 0.023 NS
Benzodiazepines 16.67% 8.33% 0.433 NS
Unmedicated 16.67% 8.33% 0.433 NS
(df = 1, n = 30)
doi:10.1371/journal.pone.0157060.t002
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surprising that ANOVA results indicated that despite very high levels of compliance across all
groups, some differences in compliance levels were evident (F(3,57) = 3.238, p = .029). Two-
tailed Scheffé all pairwise post hoc comparisons revealed that these differences were driven by
a trend in which the MJ group exhibited lower percentages for completion of EMA ratings
(M = 83.71, SD = 9.81) than the HC group (M = 93.78, SD = 5.91, p = .055). Compliance per-
centages for the BP (M = 90.08, SD = 9.90) and MJBP groups (M = 84.20, SD = 19.29) were not
significantly different from the other groups. However, due to the significant between-group
differences, EMA analyses were re-run with compliance percentage as a covariate, and results
remained unchanged. Further, in order to determine the nature of missing EMA data, correla-
tion analyses were also conducted to assess the association between compliance percentage and
EMA clinical ratings. Compliance percentage did not significantly correlate with any clinical
rating scale (r(59).203, p.12), suggesting that ratings were missing at random, and therefore
missing EMA data did not unduly influence clinical mood ratings results.
Between-group analyses. Overall average mood ratings from across the 4-week data col-
lection period are presented in Table 3. As expected, compared to the HC group, BP and MJBP
participants reported higher levels of anger, confusion, tension, fatigue, depression, and total
mood disturbance (TMD) as measured by the POMS, as well as increased anxiety (HAM-A),
depression (MADRS), and mania (YMRS). Among patients, those in the BP group reported
similar overall mood to MJBP participants, with no significant differences observed on any rat-
ing scale, with the exception of higher MADRS scores in the MJBP group. Despite this differ-
ence, depression ratings on the POMS were similar between groups, and actually were slightly
(albeit not significantly) lower in the MJBP group relative to the BP group. With regard to the
MJ group, no significant differences were noted between MJ smokers and HCs for average
mood ratings.
Analyses of average pre-MJ use mood data in the MJ and MJBP group compared to overall
average mood in the HC and BP group are presented in Table 4 (top portion of table); analyses
of average post-MJ mood data in the MJ and MJBP group compared to overall average mood in
the HC and BP group are presented in Table 4 (bottom half of table). Prior to smoking MJ, the
MJBP participants reported higher levels of anger, confusion, tension, depression, and TMD
on the POMS, as well as greater anxiety, depression, and mania as measured by the HAM-A,
MADRS, and YMRS, relative to the average mood ratings of the HC participants. After smok-
ing MJ, while some significant differences remained between the MJBP and HC groups, the
MJBP group no longer endorsed significantly higher anger, tension, or TMD on the POMS rel-
ative to the HCs. Notably, the MJ participants did not report significantly different mood rat-
ings compared to the HC participants either pre- or post-MJ use.
Two-group ANCOVAs directly comparing the BPD patient groups (BP vs MJBP; Table 4)
revealed that prior to MJ use, MJBP participants exhibited higher depression (MADRS) scores
and a trend for higher mania (YMRS) ratings relative to the BP group. Interestingly, after
smoking MJ, the MJBP group reported decreased levels of depression and mania; MADRS
scores fell to a level no longer significantly different from ratings in the BP group, and the
trend for higher mania ratings on the YMRS was no longer observed in MJBP participants rela-
tive to BP participants. In addition, the MJBP group reported a trend for lower levels of tension
on the POMS after MJ use compared to BP patients. Together, these decreases in clinical symp-
toms led to far lower TMD scores in the MJBP group afterMJ use, relative to the BP group’s
average TMD score (MJBP: 11.15 vs BP: 22.53); however, this difference was not statistically
significant.
Within-group analyses. Paired t tests investigating within-group mood changes pre- and
post MJ use suggest that after smoking MJ, the MJ smokers experienced slightly worse mood
overall. As a group, they reported significantly increased confusion and fatigue, and decreased
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vigor on the POMS, resulting in higher TMD scores relative to pre-smoking levels. It is of note,
however, that their average TMD scores still fell below zero, reflecting very low levels of mood-
related symptomatology overall. MJ smokers also reported higher levels of anxiety (HAM-A)
afterMJ use (Fig 1A). In contrast, the MJBP participants reported positive changes in mood
afterMJ use. Paired t tests comparing pre- and post-MJ use mood ratings within the MJBP
group indicated significantly decreased ratings of anger, tension, depression, and TMD scores
on the POMS as well as lower levels of depression on the MADRS. In addition, MJBP partici-
pants reported increased vigor on the POMS after MJ use (Fig 1B).
Neuropsychological Assessment
HC vs All BP: Effects of BPD on cognition (regardless of MJ use status). When all BPD
patients (BP and MJBP combined) were compared to the HC group, they generally demon-
strated poorer performance on tasks of executive function. Specifically, as noted in Table 5,
2-way ANCOVAS revealed that patients with BPD achieved fewer categories, made more per-
severation errors and had more losses of set on the WCST. Patients with BPD had significantly
longer completion times and made more errors on the Stroop during the Color Naming and
Word Reading condition. They also demonstrated slightly slower completion times on the
Stroop Interference condition relative to the HCs, although this did not reach statistical signifi-
cance. Similarly, BPD patients also performed Trails B significantly more slowly and exhibited
Table 3. ANCOVAs (controlling for age differences) of the 4-group (HC, MJ, BP, MJBPwith Dunnett t post hoc comparisons) and 2-group (BP v
MJBP) comparisons of overall 4-week average mood EMA ratings (1-tailed).
Variable HC MJ BP MJBP 4-group ANCOVA 4-group Dunnett t Post Hoc
Comparisons
2-group BP v
MJBP ANCOVA
F p (η2) HC v
MJ
HC v
BP
HC v
MJBP
F p (η2)
n 18 21 12 10 - - - - - - -
POMS
Vigor 11.13
(3.77)
12.92
(4.73)
9.71 (3.67) 9.39 (3.23) 2.039 .060 (.098) NS NS NS 0.357 .279
(.018)
Anger 0.86 (0.76) 1.31 (1.71) 4.24 (3.41) 4.14 (2.59) 7.616 <.001
(.290)
NS <.001 <.001 0.355 .279
(.018)
Confusion 3.48 (1.44) 3.51 (1.81) 7.06 (3.39) 5.76 (2.69) 5.951 <.001
(.242)
NS <.001 .019 0.022 .442
(.001)
Tension 3.27 (1.30) 2.71 (1.61) 6.92 (3.37) 6.48 (3.94) 7.851 <.001
(.296)
NS <.001 .003 0.187 .335
(.010)
Fatigue 3.07 (1.86) 2.00 (1.65) 7.06 (3.48) 5.08 (2.99) 8.843 <.001
(.321)
NS <.001 .050 0.219 .323
(.011)
Depression 1.31 (1.37) 1.06 (2.07) 6.95 (7.04) 6.61 (5.17) 6.462 .001 (.257) NS <.001 .002 0.570 .230
(.029)
TMD 0.86 (7.58) -2.33 (9.52) 22.53
(21.17)
18.68
(17.41)
8.686 <.001
(.318)
NS <.001 .002 0.196 .332
(.010)
HAMA 0.68 (0.65) 0.86 (1.23) 4.43 (3.44) 4.82 (3.92) 9.904 <.001
(.347)
NS <.001 <.001 0.771 .120
(.039)
MADRS 1.52 (1.37) 1.57 (2.00) 7.21 (5.43) 10.60 (7.01) 14.832 <.001
(.443)
NS <.001 <.001 3.183 .045
(.143)
YMRS 1.56 (0.84) 1.50 (1.42) 3.99 (3.23) 5.64 (2.83) 8.193 <.001
(.305)
NS .008 <.001 1.693 .105
(.082)
POMS = Proﬁle of Mood States, TMD = Total Mood Disturbance, HAM-A = Hamilton Anxiety Rating Scale, MADRS = Montgomery-Asberg Depression
Rating Scale, YMRS = Young Mania Rating Scale.
doi:10.1371/journal.pone.0157060.t003
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Table 4. Pre- vs Post-MJ Use Mood in MJ and MJBP Participants: ANCOVAs (controlling for age differences) of the 4-group (HC, MJ, BP, MJBP
with Dunnett t post hoc comparisons) and 2-group (BP v MJBP) comparisons of overall 4-week averagemood in the HC and BP participants to
average pre- and post-MJ use mood in the MJ and MJBP participants (1-tailed).
Variable HC (avg) MJ (pre) BP (avg) MJBP (pre) 4-group ANCOVA 4-group Dunnett t Post Hoc
Comparisons
2-group ANCOVA
BP v MJBP
F p (η2) HC v
MJ
HC v
BP
HC v
MJBP
F p (η2)
n 18 21 12 10 - - - - - - -
PRE MJ USE
POMS
Vigor 11.13
(3.77)
13.67 (5.50) 9.71 (3.67) 9.26 (2.96) 2.792 .025 (.130) NS NS NS 0.672 .211
(.034)
Anger 0.86 (0.76) 1.29 (1.84) 4.24 (3.41) 4.52 (3.14) 7.604 <.001
(.289)
NS <.001 <.001 0.728 .202
(.037)
Confusion 3.48 (1.44) 3.00 (1.64) 7.06 (3.39) 6.43 (2.96) 8.455 <.001
(.312)
NS <.001 .003 0.133 .360
(.007)
Tension 3.27 (1.30) 2.69 (2.12) 6.92 (3.37) 7.53 (4.41) 8.933 <.001
(.324)
NS .001 <.001 1.166 .147
(.058)
Fatigue 3.07 (1.86) 1.68 (1.70) 7.06 (3.48) 4.77 (3.05) 9.290 <.001
(.332)
NS <.001 NS 0.464 .252
(.024)
Depression 1.31 (1.37) 0.71 (1.11) 6.95 (7.04) 7.40 (6.06) 8.086 <.001
(.302)
NS <.001 <.001 0.904 .177
(.045)
TMD 0.86 (7.58) -4.30 (8.86) 22.53
(21.17)
21.39
(19.68)
10.608 <.001
(.362)
NS <.001 <.001 0.590 .226
(.030)
HAMA 0.68 (0.65) 0.61 (1.13) 4.43 (3.44) 5.06 (4.15) 10.997 <.001
(.371)
NS <.001 <.001 0.980 .168
(.049)
MADRS 1.52 (1.37) 1.41 (1.63) 7.21 (5.43) 11.91 (7.53) 18.538 <.001
(.498)
NS <.001 <.001 5.317 .017
(.219)
YMRS 1.56 (0.84) 1.90 (2.44) 3.99 (3.23) 6.10 (3.89) 7.762 <.001
(.294)
NS .020 <.001 2.084 .083
(.009)
POST MJ USE
POMS
Vigor 11.13
(3.77)
12.02 (4.65) 9.71 (3.67) 10.78 (3.52) 0.656 .292 (.034) NS NS NS 0.095 .381
(.005)
Anger 0.86 (0.76) 1.43 (1.78) 4.24 (3.41) 2.35 (2.54) 4.840 .003 (.206) NS <.001 NS 0.953 .171
(.048)
Confusion 3.48 (1.44) 3.63 (1.68) 7.06 (3.39) 5.85 (3.11) 5.771 .001 (.236) NS <.001 .017 0.021 .443
(.001)
Tension 3.27 (1.30) 2.54 (1.66) 6.92 (3.37) 4.15 (2.62) 7.707 <.001
(.292)
NS <.001 NS 2.473 .066
(.115)
Fatigue 3.07 (1.86) 2.77 (2.72) 7.06 (3.48) 4.88 (3.24) 5.186 .002 (.217) NS <.001 NS 0.430 .260
(.022)
Depression 1.31 (1.37) 0.77 (1.23) 6.95 (7.04) 4.69 (3.64) 6.073 .001 (.245) NS <.001 .026 0.030 .433
(.002)
TMD 0.86 (7.58) -0.87
(10.32)
22.53
(21.17)
11.15
(13.69)
6.626 .001 (.262) NS <.001 NS 0.511 .242
(.026)
HAMA 0.68 (0.65) 0.82 (1.08) 4.43 (3.44) 4.23 (4.12) 8.315 <.001
(.308)
NS <.001 <.001 0.065 .401
(.003)
MADRS 1.52 (1.37) 1.46 (1.71) 7.21 (5.43) 9.35 (6.89) 12.229 <.001
(.397)
NS <.001 <.001 1.341 .131
(.066)
YMRS 1.56 (0.84) 2.30 (1.96) 3.99 (3.23) 5.61 (3.81) 6.856 .001 (.269) NS .013 <.001 1.091 .155
(.054)
POMS = Proﬁle of Mood States, TMD = Total Mood Disturbance, HAM-A = Hamilton Anxiety Rating Scale, MADRS = Montgomery-Asberg Depression
Rating Scale, YMRS = Young Mania Rating Scale.
doi:10.1371/journal.pone.0157060.t004
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a trend for more errors on Trails A relative to HCs. BPD patients achieved lower total scores
across the three trials of the COWAT in which they had to generate words starting with a given
letter (F, A, S); during the semantic category trial (animals) a trend was also observed for fewer
words generated among BPD patients. In addition, BPD patients recalled fewer digits on Digit
Span overall, including recollection of digits in forward order (Forward) and in reverse order
(Backward), which led to lower Total Digit Span scores.
On the remaining measures, BPD patients also tended to demonstrate reduced perfor-
mance. Despite similar scores on the copy condition of the ROCF, they exhibited slightly lower
scores on the immediate recall condition, and achieved significantly lower scores on delayed
recall relative to the HCs. On the CVLT, BPD patients recalled fewer words during the initial
learning trial (Trial 1), as well as across all five trials (Trial 1–5 Total Correct), and after the
Long Delay. They also used less semantic clustering on the CVLT across the five trials (Trial
1–5 Total Semantic Clusters). No significant differences in performance were apparent on the
HVOT.
HC vs BP: Effects of BPD on cognition (exclusive of MJ use). Post hoc analyses from a
three-way ANCOVA comparing HC, BP and MJBP patients revealed that, relative to HCs, the
non-MJ smoking BP participants (BP group only) demonstrated similar deficits when exam-
ined separate from the MJBP group as when grouped with MJBP participants (see Table 5).
The BP group exhibited poorer performance across the majority of assessment measures. Non-
MJ smoking BP patients achieved significantly fewer categories on the WCST; they also made
more perseverative errors, and had more losses of set, although this did not reach the threshold
for significance. Participants in the BP group also made more errors on the Stroop Color Nam-
ing and Word Reading subtests. They took significantly longer to complete Trails B, and exhib-
ited a trend for more Trails B errors. Further, they recalled slightly fewer digits across on Digit
Span Backwards, which contributed to significantly lower scores on the Total Digit Span scores
among BPD patients relative to HCs. On the CVLT, the BP group recalled fewer words than
Fig 1. Paired t-Test EMAAnalyses of Clinical State Pre- versus Post-MJ Use. EMA analyses of clinical state (POMS,
HAMA, MADRS, YRMS) changes pre- versus post-MJ use in the (A) MJ group and (B) MJBP group revealed a slight
worsening of symptoms in the MJ group after smoking MJ but a significant mood improvement in the MJBP group after smoking
MJ, *t(9)1.942, p.042, 1-tailed. POMS = Profile of Mood States, TMD = Total Mood Disturbance, HAM-A = Hamilton
Anxiety Rating Scale,MADRS =Montgomery-Asberg Depression Rating Scale, YMRS = YoungMania Rating Scale
doi:10.1371/journal.pone.0157060.g001
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Table 5. Neuropsychology Data and Between-Groups Comparisons: ANCOVAs (controlling for age) of the 2-group (HC v All BP) and 3-group (HC,
BP, and MJBP) comparisons (2-tailed).
Variable HC All BP BP MJBP 2-group ANCOVA
HC v All BP
3-group
ANCOVA HC v
BP v MJBP
Scheffé All Pairwise Post Hoc
Comparisons
F p (η2) F p (η2) HC vs
BP
HC vs
MJBP
BP vs
MJBP
n 21 30 18 12 - - - - - - -
WCST
Total Categories 9.30 (0.98) 8.21 (1.26) 8.29 (1.31) 8.08 (1.24) 9.598 .003
(.173)
4.858 .012
(.178)
.041 .023 NS
Total Perseverations 6.40 (4.44) 10.72
(7.30)
10.00
(7.16)
11.75
(7.69)
5.718 .021
(.111)
2.996 .060
(.118)
NS .080 NS
Total Losses of Set 0.15 (0.37) 0.59 (0.87) 0.59 (0.87) 0.58 (0.90) 4.694 .035
(.093)
2.318 .110
(.093)
NS NS NS
Stroop
Color Naming Time
(sec)
49.60
(7.47)
54.33
(9.01)
52.17
(7.29)
57.58
(10.61)
4.148 .047
(.081)
3.444 .040
(.130)
NS .038 NS
Color Naming Errors 0.55 (1.00) 1.37 (1.33) 1.67 (1.50) 0.92 (0.90) 5.495 .023
(.105)
4.811 .013
(.173)
.021 NS NS
Word Reading Time
(sec)
38.95
(4.39)
42.10
(5.82)
41.56
(5.95)
42.92
(5.78)
6.539 .014
(.122)
3.201 .050
(.122)
NS NS NS
Word Reading Errors 0.35 (0.59) 0.93 (1.05) 1.11 (1.08) 0.67 (0.98) 5.041 .029
(.097)
3.781 .030
(.141)
.039 NS NS
Interference Time
(sec)
85.75
(15.60)
91.63
(15.94)
89.56
(16.13)
94.75
(15.82)
2.763 .103
(.056)
1.435 .248
(.059)
NS NS NS
Interference Errors 2.10 (1.94) 2.03 (2.11) 2.33 (2.35) 1.58 (1.68) 0.046 .831
(.001)
1.172 .319
(.048)
NS NS NS
Trail Making Test
A Time (sec) 20.85
(6.29)
24.07
(8.55)
23.33
(6.45)
25.17
(11.24)
1.919 .173
(.039)
1.160 .322
(.048)
NS NS NS
A Errors 0.10 (0.31) 0.30 (0.53) 0.39 (0.61) 0.17 (0.39) 3.351 .074
(.067)
3.655 .034
(.137)
NS NS NS
B Time (sec) 38.85
(11.21)
54.23
(19.86)
55.50
(21.75)
52.33
(17.38)
7.670 .008
(.140)
3.770 .030
(.141)
.016 NS NS
B Errors 0.15 (0.49) 0.40 (0.62) 0.56 (0.70) 0.17 (0.39) 0.992 .663
(.004)
1.356 .268
(.056)
.093 NS NS
COWAT
Total (FAS) 47.65
(8.78)
39.14
(11.58)
38.25
(11.69)
40.20
(11.98)
7.318 .010
(.158)
3.835 .030
(.168)
.060 NS NS
Semantic Category 26.45
(6.42)
22.59
(4.82)
22.25
(5.67)
23.00
(3.80)
3.146 .084
(.075)
1.552 .225
(.076)
NS NS NS
Digit Span
Forward 9.80 (2.09) 8.50 (2.35) 8.24 (2.54) 8.91 (2.07) 4.262 .045
(.087)
2.681 .080
(.109)
NS NS NS
Backward 8.85 (2.50) 7.18 (1.87) 7.18 (2.24) 7.18 (1.17) 9.792 .003
(.179)
5.063 .010
(.187)
.077 NS NS
Total 18.65
(4.06)
15.68
(3.58)
15.41
(4.06)
16.09
(2.81)
8.993 .004
(.167)
5.009 .001
(.185)
.046 NS NS
ROCF
Copy 33.00
(2.92)
30.93
(3.71)
31.04
(4.45)
30.80
(2.79)
2.491 .123
(.063)
1.325 .278
(.069)
NS NS NS
Immediate 22.69
(7.55)
16.93
(7.30)
16.83
(8.26)
17.05
(6.41)
3.019 .091
(.075)
1.778 .184
(.090)
NS NS NS
(Continued)
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HCs on the CVLT across all five trials and after a delay. On the COWAT and ROCF, although
results were not significant, the BP group demonstrated several trends for worse performance,
as noted in Table 5. No deficits were noted the HVOT between HCs and the BP group.
HC vs MJ: Effects of MJ use on cognition (exclusive of BPD diagnosis). Similar to our
previous report of MJ smokers [43], two-way ANCOVAs directly comparing MJ smokers to
HCs demonstrated that pure MJ smokers exhibited impairment on a number of tasks relative
to HCs, including the WCST, Trail Making Test, COWAT, and CVLT (See Table 6). Specifi-
cally, as noted in the BPD patients, MJ smokers demonstrated poorer executive functioning rel-
ative to controls. They achieved fewer categories and made more perseverative errors on the
WCST, and took longer to complete Trails B of the Trail Making Test. MJ smokers generated
fewer words than HCs on the COWAT when asked to provide words in a given semantic cate-
gory. On the CVLT, although MJ smokers recalled a similar number of correct words, they had
more Intrusions (incorrect responses) and utilized less semantic clustering across trials (Total
Semantic Clusters). HC and MJ participants did not differ significantly with regard to their per-
formance of the Stroop Color Word Test, Digit Span, ROCF, or HVOT.
HC vs MJBP and BP vs MJBP: Potential additive effects of BPD and MJ use. Post hoc
analyses from three-way ANCOVAs (HC vs BP vs MJBP) designed to detect potential additive
effects of BPD and MJ use revealed that MJBP patients demonstrated some areas of poorer cog-
nitive performance relative to HCs (see Table 5, HC vs MJBP). They achieved fewer categories
on the WCST and their performance suggests a trend for making more perseverative errors on
this task. On the Stroop, significantly slower times were noted relative to HCs on the Color
Naming subtest, while on the CVLT, MJBP participants recalled significantly fewer words
Table 5. (Continued)
Variable HC All BP BP MJBP 2-group ANCOVA
HC v All BP
3-group
ANCOVA HC v
BP v MJBP
Scheffé All Pairwise Post Hoc
Comparisons
F p (η2) F p (η2) HC vs
BP
HC vs
MJBP
BP vs
MJBP
n 21 30 18 12 - - - - - - -
Delay 22.81
(6.82)
16.68
(6.58)
16.63
(6.91)
16.75
(6.54)
4.957 .031
(.118)
2.660 .084
(.129)
.062 .091 NS
CVLT
Trial 1 Correct 8.25 (1.89) 6.46 (1.91) 6.88 (1.83) 5.82 (1.94) 8.997 .004
(.167)
6.005 .005
(.214)
NS .005 NS
Total Correct 61.10
(8.14)
51.18
(10.53)
53.35
(11.75)
47.82
(7.61)
10.182 .003
(.185)
7.192 .002
(.246)
.057 .002 NS
Total Perseverations 4.75 (5.44) 5.57 (4.76) 5.29 (4.78) 6.00 (4.94) 0.331 .568
(.007)
0.212 .810
(.010)
NS NS NS
Total Intrusions 1.60 (2.14) 1.11 (2.74) 0.53 (1.23) 2.00 (4.05) 0.669 .418
(.015)
2.130 .131
(.088)
NS NS NS
Total Semantic
Clusters
27.10
(11.09)
18.57
(13.01)
21.47
(14.82)
14.09
(8.34)
4.393 .042
(.089)
4.262 .020
(.162)
NS .023 NS
Long Delay Correct 13.90
(1.68)
10.64
(3.68)
10.65
(4.14)
10.64
(3.04)
10.328 .002
(.187)
5.239 .009
(.192)
.009 .024 NS
HVOT
Total 26.56
(1.76)
26.41
(1.88)
25.71
(2.03)
27.25
(1.34)
0.016 .901
(<.001)
2.063 .142
(.103)
NS NS NS
WCST = Wisconsin Card Sorting Test, ROCF = Rey-Osterrieth Complex Figure, COWAT = Controlled Oral Word Association Test, CVLT = California
Verbal Learning Test, HVOT = Hooper Visual Organization Test.
doi:10.1371/journal.pone.0157060.t005
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during Trial 1, throughout all five learning trials, and after a 20-minute delay. MJBP partici-
pants also had fewer semantic clusters on the CVLT. On the ROCF, like the pure BP group,
MJBP participants exhibited a trend for lower scores on the Delayed Recall; however, they did
not exhibit impairment on the remaining conditions of the task, nor did they demonstrate
impaired performance on the Trail making Test, Digit Span, or HVOT relative to HCs.
Table 6. Neuropsychology Data and Between-Groups Comparisons: ANCOVAs (controlling for age differences) of the 2-group (HC v MJ) compari-
sons (1-tailed).
Variable HC MJ 2-group ANCOVA
F p (η2)
n 20 23
WCST
Total Categories 9.30 (0.98) 8.73 (1.55) 6.746 .007 (.147)
Total Perseverations 6.40 (4.44) 10.50 (8.55) 12.680 .001 (.245)
Total Losses of Set 0.15 (0.37) 0.36 (0.73) 2.502 .061 (.060)
Stroop Color Word Test
Color Naming Time (sec) 49.60 (7.47) 52.26 (8.43) 1.449 .118 (.035)
Color Naming Errors 0.55 (1.00) 1.09 (1.12) 2.281 .070 (.054)
Word Reading Time (sec) 38.95 (4.39) 39.65 (4.51) 0.256 .308 (.006)
Word Reading Errors 0.35 (0.59) 0.43 (0.59) 0.248 .311 (.006)
Interference Time (sec) 85.75 (15.60) 86.96 (14.50) 0.273 .302 (.007)
Interference Errors 2.10 (1.94) 2.65 (2.25) 0.802 .188 (.020)
Trail Making Test
A Time (sec) 20.85 (6.29) 20.95 (4.53) 0.122 .365 (.003)
A Errors 0.10 (0.31) 0.18 (0.39) 0.231 .317 (.006)
B Time (sec) 38.85 (11.21) 50.50 (22.65) 4.784 .018 (.109)
B Errors 0.15 (0.49) 0.32 (0.48) 0.863 .180 (.022)
COWAT
Total (FAS) 47.65 (8.78) 48.45 (11.43) 0.035 .426 (.001)
Semantic Category 26.45 (6.42) 21.86 (5.59) 7.134 .006 (.155)
Digit Span
Forward 9.80 (2.09) 9.78 (2.39) 0.010 .462 (<.001)
Backward 8.85 (2.50) 8.70 (2.24) 0.113 .370 (.003)
Total 18.65 (4.06) 18.48 (3.82) 0.021 .443 (.001)
ROCF
Copy 33.00 (2.92) 32.72 (3.33) 0.206 .327 (.005)
Immediate 22.69 (7.55) 22.42 (7.01) 0.078 .391 (.002)
Delayed 22.81 (6.82) 22.07 (6.65) 0.239 .314 (.006)
CVLT
Trial 1 Correct 8.25 (1.89) 7.39 (2.41) 2.381 .065 (.056)
Total Correct 61.10 (8.14) 57.52 (8.95) 2.717 .054 (.064)
Total Perseverations 4.75 (5.44) 5.57 (5.47) 0.155 .348 (.004)
Total Intrusions 1.60 (2.14) 0.57 (0.90) 3.637 .032 (.083)
Total Semantic Clusters 27.10 (11.09) 21.61 (8.52) 4.347 .022 (.098)
Long Delay Correct 13.90 (1.68) 13.09 (3.13) 2.596 .058 (.061)
HVOT 26.56 (1.76) 26.80 (2.18) 0.133 .359 (.004)
WCST = Wisconsin Card Sorting Test, ROCF = Rey Osterrieth Complex Figure, COWAT = Controlled Oral Word Association Test, CVLT = California
Verbal Learning Test, HVOT = Hooper Visual Organization Test
doi:10.1371/journal.pone.0157060.t006
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Although BPD patients and MJ smokers each demonstrated impairment on several mea-
sures of cognitive performance relative to HCs, no differences emerged when directly compar-
ing the BP and MJBP groups (see Table 5, BP vs MJBP). In fact, Scheffé all pairwise post hoc
comparisons revealed no significant between-group differences for BP vs MJBP participants
for any task: WCST, Stroop, Trail Making Test, COWAT, CVLT, ROCF, Digit Span, or
HVOT.
Discussion
The current investigation, to our knowledge, marks the first study to examine the effects of MJ
on both mood and neuropsychological performance in BPD patients. As the nation explores
indications for medical MJ (MMJ), it is imperative to determine howMJ use might affect clini-
cal symptoms in those diagnosed with mood disorders, such as BPD. In addition, given the fact
that cognitive decrements are well-documented in both MJ smokers [43, 62–64] and those
with BPD [39, 65], it is critical to examine whether these impairments may be exacerbated or
possibly ameliorated by the combination of a BPD diagnosis and regular MJ use. Through the
utilization of proper control groups (achieved by including four discrete groups: healthy con-
trols, MJ smokers with no Axis I pathology, non-MJ smoking BP patients, and MJ-smoking BP
patients), the current study was able to begin to clarify both the individual effects and potential
for additive effects of MJ use and BPD on mood and cognition.
As hypothesized, our findings suggest that after smoking MJ, BPD patients experienced
improvement in several aspects of clinical state secondary to MJ use. In fact, direct analyses of
the MJ-smoking BPD patients (MJBP) before and afterMJ use revealed notable symptom alle-
viation within four hours of smoking. After smoking MJ, the MJBP group reported signifi-
cantly lower scores of anger, tension, depression (POMS and MADRS), as well as higher levels
of vigor, which led to a marked decrease in TMD scores (22.39 to 11.15), a composite measure
of overall mood on the POMS. Further, prior to smoking MJ, the MJBP participants reported
slightly worse levels of symptomatology relative to the pure BP group, with higher levels of
depressive and manic symptoms. In contrast, after MJ use, the MJBP group demonstrated con-
siderably lower levels of tension and lower TMD scores relative to the BP group. In addition,
although depression (MADRS) and mania scores were still slightly higher in the MJBP group
after MJ use relative to the BP group, scores dropped to levels that were no longer significant or
approaching significance between the two groups, highlighting positive changes in mood-
related symptoms. In addition, average mood ratings across the course of the study showed
that overall mood was comparable between MJBP and BP subjects. Although MADRS scores
were generally elevated in MJBP patients, POMS scores for depression were similar between
groups (and were actually marginally lower within MJBP participants). As the MADRS reflects
specific depressive symptoms, as compared to the POMS which measures self-perceived mood,
results may indicate that while certain depressive symptoms were more evident in MJBP partic-
ipants relative to BP participants, a self-perceivedmood of depression (i.e., feeling sad, lonely,
blue) was not more prevalent in MJBP participants.
To some extent, these findings support recent work, which found that MJ use was correlated
with increased positive affect in BPD patients [66]. However, the authors also observed a rela-
tionship between MJ use and increased manic and depressive symptoms. Although the authors
of this study report both positive and negative fluctuations in clinical symptoms, they posit
that bidirectional effects of MJ use, outlined by Ashton and colleagues [22], are likely impacted
by a range of factors, including dose, mode of use, and personality differences. In addition, as
we learn more about the differential effects of individual constituents of MJ, (i.e., THC vs can-
nabidiol [CBD]), it is possible that strains higher in certain constituents are at least partially
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responsible for the moderation of specific dimensions of clinical symptoms. Some research
suggests that CBD may be beneficial in alleviating, anxiety, psychosis, and other psychological
symptoms [67–70] and may have a pharmacological profile similar to that of antipsychotic
medications [69], which are often prescribed to patients with bipolar I disorder. Further, CBD
has been shown to be an effective anticonvulsant treatment for those with pediatric seizure dis-
orders [70], another class of drugs frequently prescribed for mood stabilization in patients with
BPD.
Interestingly, among pure MJ smokers (those not diagnosed with BPD), beneficial effects on
mood were not observed in the current study. MJ smokers reported decreases in vigor, as well
as higher levels of confusion, fatigue and TMD after smoking, consistent with effects com-
monly reported in the general population after MJ use. It is of note, however, that MJ smokers
continued to exhibit very low levels of mood-related symptoms even after MJ use, suggesting
that while their mood did appear to worsen slightly after using MJ, these changes remained far
below clinical thresholds. Overall, results may indicate that MJ use may have unique effects in
BPD patients, effects which are not necessarily observed in those without Axis I pathology.
With regard to cognitive performance, MJ smokers and BPD patients performed more
poorly than HCs overall. However, within the BPD patients, impairment was observed regard-
less of MJ use status; deficits were apparent when the non-smoking BP patients were analyzed
as a whole group (BP and MJBP) as well as separately (BP vs MJBP). Overall, patients in both
BPD groups demonstrated poorer performance on tasks of executive function. They also exhib-
ited less efficient learning and recall strategies during a serial list-learning task, reduced verbal
fluency, inferior attention and working memory, and poorer visuospatial organization. Inter-
estingly, when the non-smoking BP group was compared to the MJBP group, no significant dif-
ferences across any measure were noted. Taken together, study findings suggest that MJ use
may result in at least short-term mood term stabilization for a subset of BPD patients, and fur-
ther, that MJ use does not have an additive, negative impact on cognitive performance in BPD
patients.
These findings provide a valuable contribution to the field, which has only begun to clarify
the effects of MJ on mood and cognition in psychiatric populations. While many would posit
that the individual relationships between cognitive impairment and both MJ use and BPD
would collectively result in amore severe impact on cognitive function, some studies have actu-
ally reported a cognitive advantage in BPD patients who use MJ regularly [40–41]. In addition,
a recent study of MJ-smoking patients diagnosed with schizophrenia found no evidence for an
additive effect of MJ use and schizophrenia diagnosis on cognitive dysfunction [71]. In combi-
nation, these studies provide evidence that cognitive deficits associated with certain Axis I
pathologies may not be worsened by MJ use. In fact, improved cognitive performance may be
related to the potential anxiolytic effects of MJ. Anxiety, common in BPD patients [72], often
interferes with attention and the ability to encode information, suggesting that if MJ acts as an
anxiolytic in at least a subset of patients, this may result in better concentration and enhanced
cognitive performance.
Despite these positive changes, one previous study also observed that patients tended to
experience improved cognitive performance at the expense of a more severe clinical course
[41]. While the current study did not examine long-term treatment outcomes, our preliminary
findings provide evidence that BPD patients who smoke MJ may derive at least a short-term
clinical benefit. MJBP participants reported improvements in mood within four hours of smok-
ing MJ, did not have elevated average mood ratings (with the exception of the MADRS) relative
to the BPD group across the four-week study, and did not experience additional cognitive defi-
cits when compared to the non-smoking BP group. Future studies will need to be conducted
in order to investigate the effect of MJ use on clinical course over longer durations of time.
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Limitations
Data from the current study provide critical information about MJ use in psychiatric popula-
tions, as guidelines regarding indications for medical MJ are considered; however, these find-
ings must be interpreted in light of several limitations. First, although this study served as a
pilot investigation, it is important to acknowledge that the overall sample is moderate in size,
with a modest number of patients completing EMA ratings, which may limit the generalizabil-
ity of findings. For example, only participants who were well characterized as chronic, heavy
MJ smokers were enrolled in the current study; participants with less frequent use (i.e., casual
MJ smokers) may not experience the same effects of MJ on mood and cognition as observed in
this sample of participants. Further, rather stringent enrollment criteria were employed, which
excluded participants who reported comorbid diagnoses (via phone interview or through the
clinical interview). In addition, participants were required to be predominantly euthymic
throughout the course of the study. Although these criteria limited the effects of extraneous
variables, the impact of MJ on mood and cognition may differ in those who have been diag-
nosed with comorbid disorders (i.e., ADHD, PTSD, polysubstance use, etc.) or who may be
experiencing more acute clinical symptomatology. Finally, likely related to the geographic
region from which patients were recruited (the Greater Boston area is home to many universi-
ties, hospitals, and research institutions), participants generally demonstrated higher than aver-
age IQs. This may limit generalizability to populations with average to below average cognitive
abilities. It will be important for future studies to recruit larger numbers of research partici-
pants to further investigate the impact of MJ on mood and cognition in BPD, as well as to
examine additional factors that were not explored in the current pilot investigation.
Additionally, although the four groups were not statistically matched for sex (more males
were enrolled than females in the MJ and MJBP groups), it is likely that the sex distribution of
this sample is actually representative of the larger population. In fact, national surveys of sub-
stance-using populations have revealed that males engage in the use of illicit substances,
including MJ, more frequently than females [73–74].
Regarding the EMA study design, overall compliance was very high among all study groups
with an overall completion rate of 88% of all possible scheduled ratings. Several measures were
also put in place to encourage completion of ratings after MJ use, including comparing
reported frequency of MJ use during interim visits to the frequency of EMA ratings. However,
given the nature of EMA data, it is not possible to guarantee that all participants completed
mood ratings immediately after MJ use. In an attempt to address this issue, all participants
were asked to adjust the time of last use if necessary, and any ratings reported more than four
hours after MJ use were not coded as post-use data. While this four-hour window was selected
to capture the acute effects of MJ use on mood, the duration of MJ effects are likely related to a
range of factors including, but not limited to the specific product used (i.e. high THC/low
THC), amount and frequency of use, mode of use, and metabolism. It may therefore be an
important consideration for future studies to explore whether the duration of MJ intoxication
is related to the duration of reported symptom improvement by BPD participants.
Further, although this investigation examined the acute effects of MJ use in BPD patients,
additional investigations should explore the potential long-term impact of MJ use on clinical
state. It is of note that over the duration of the study, the overall average mood ratings for the
MJBP and BP were not significantly different across any measure (except for the MADRS),
which provides preliminary evidence that MJ use may not directly result in poorer clinical
course. Higher levels of clinical severity previously reported in MJ-smoking BPD patients [4, 8,
11] may be a result of several factors, including a failure to inform clinicians of MJ use. As MJ
may partially address mood-related symptoms, the pharmacotherapeutic regimen prescribed
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by physicians may, as a result, be different from what would normally be prescribed. Addition-
ally, any short-term improvement following MJ use may result in non-adherence with patients’
prescribed medications, which could ultimately result in poorer long-term outcomes.
Due to the preliminary nature of the current study, the relationship between specific pat-
terns or levels of MJ use and symptom improvement were not thoroughly investigated. In addi-
tion, all MJ using participants in the current study were chronic MJ users and results may
therefore not be generalizable to more casual MJ users. Future investigations should consider
the impact of frequency and amount of MJ smoked, as well as mode of use, and strain of MJ
used on both cognition and symptomotology. In fact, several studies have shown promise for
the alleviation of anxiety using MJ products that contain high levels of CBD [67–68]. Given
that CBD is a non-psychoactive phytocannabinoid that has shown promise as an anxiolytic
and anticonvulsant (often used to stabilize mood in patients with BPD), high CBD-containing
products may afford more viable options than other cannabinoid-based treatments. Therefore,
future studies should also aim to explore whether high-CBD relative to low-CBD strains have
differential effects in BPD patients as well as other clinical populations.
Finally, it should be noted the current study design does not imply cause and effect, but
rather shows a relationship between MJ use and mood improvement. Clinical trials will be
needed in order to further investigate the potential for MJ and cannabinoid-containing prod-
ucts as a potential treatment for patients with BPD.
Conclusions
New legislation across the nation has increased the overall accessibility of MJ to the general
public for both recreational and medical use. To date, 24 states and the District of Columbia
have fully legalized medical marijuana and another 18 states have allowed the use of CBD-
based products for medical use. Each state individually regulates the use of MMJ, and perhaps
not surprisingly, a wide range of acceptable conditions are often listed as eligible for MMJ certi-
fication. While some states include a “catchall” category, allowing physicians to certify condi-
tions at their discretion, other states employ a restrictive list of indications suitable for MMJ.
Additional studies are needed to help shape public policy regarding conditions that may be
amenable to MMJ treatment, especially with regard to psychiatric illnesses. The current study
highlights preliminary evidence that patients with BPD who regularly smoked MJ reported at
least short-term clinical symptom alleviation following MJ use, indicating potential mood-
stabilizing properties of MJ in at least a subset of patients with BPD. Furthermore, despite pre-
vious research showing that MJ use and BPD individually can have a negative impact on cogni-
tion, MJ use in BPD patients may not result in additional impairment. Further research is
warranted to explore the impact of MJ on mood in clinical and non-clinical populations.
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